EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer
Boston, MA, – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs
EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPS
Edinburgh, UK and Bethesda, MD, USA, 27 January 2026 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, today announces the first